BioSpace News Archive

4basebio AG (Frankfurt: 4BSB; ISIN: DE000A2YN801; Prime Standard) today announced that the Company has completed the name change from Expedeon AG to 4basebio AG

Abivax (Euronext Paris: FR0012333284 – ABVX), a clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, today announced that the U.S. Food and Drug Administration (FDA) has approved an investigational new drug (IND) application for their lead drug candidate ABX464, allowing the initiation of clinical trials in the U.S. in patients with moderate-to-severe ulcerative colitis (UC).

Applied Genetic Technologies Corporation announced that it plans to release interim six-month data from the dose escalation groups, and an update of enrollment for its ongoing CNGB3 and CNGA3 Phase 1/2 clinical trials in patients with achromatopsia on January 23, 2020.

Xenon Pharmaceuticals Inc. announced that it has commenced an underwritten public offering of its common shares pursuant to its existing shelf registration statement.

Biohaven Pharmaceutical Holding Company Ltd. announced that the U.S. Food and Drug Administration has notified its collaborators at the Sean M. Healey & AMG Center for Amyotrophic Lateral Sclerosis at Massachusetts General Hospital that they may proceed with clinical investigation of verdiperstat, Biohaven’s novel myeloperoxidase inhibitor, in ALS.

Vir Biotechnology, Inc., a clinical-stage immunology company focused on immune approaches to treating and preventing serious infectious diseases, is issuing the following in response to inquires from multiple academic, government, investor, and media stakeholders.

Myriad Genetics, Inc., a leader in molecular diagnostics and precision medicine, announced that it has submitted a supplementary premarket approval application to the U.S. Food and Drug Administration for its myChoice® CDx test to help predict outcomes of women with first-line platinum responsive advanced ovarian cancer treated with GSK’s PARP inhibitor Zejula®.

Technavio has announced its latest market research report titled global nebulizers market 2020-2024.

Blueprint Medicines Corporation announced the pricing of an underwritten public offering of 4,710,144 shares of its common stock at a public offering price of $69.00 per share, before underwriting discounts and commissions.

Agilent Technologies Inc. (NYSE: A) today announced that both The Analytical Scientist and The Medicine Maker have honored the Agilent InfinityLab LC/MSD iQ system with 2019 Innovation Awards.